Several agents have now been tested in clinical trials, with osimertinib recently approved by the US Food and Drug Administration (FDA) and other regulatory agencies in patients with EGFR T790M mutant NSCLC post failure of first-/second-generation TKIs. This evidence concerns the gene EGFR and non-small cell lung carcinoma.